GlassScriptPhysician profile
Lani B Stearns
NPI 1821745852
$9,555.11
in general payments reported to CMS, 2019-2025
56 companies · $2,522 in 2025
The $2,522 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $396 · 2023: $2,595 · 2024: $4,042 · 2025: $2,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,654 · Long Term Medical Supply Or Device Loan: $1,048 · Education: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,654.23 |
| Long Term Medical Supply Or Device Loan | $1,047.59 |
| Education | $456.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,699.97 | 2023-2025 | |
| Pfizer INC. | $734.04 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $593.76 | 2023-2025 | Opdivo, Eliquis, Augtyro |
| Daiichi Sankyo INC. | $584.12 | 2022-2025 | Injectafer, Enhertu, Datroway |
| Janssen Biotech, INC. | $536.87 | 2022-2025 | Darzalex, Tecvayli, Rybrevant |
| Celgene Corporation | $470.08 | 2022-2025 | Reblozyl, Pomalyst, Opdivo |
| Genzyme Corporation | $353.77 | 2022-2025 | |
| Eisai INC. | $331.54 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $326.36 | 2022-2025 | Lynparza, Tagrisso, Calquence |
| Seagen INC. | $299.18 | 2022-2023 | Adcetris, Tukysa |
| Gilead Sciences, INC. | $293.68 | 2023-2025 | Trodelvy |
| Abbvie INC. | $291.91 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $260.07 | 2022-2025 | Keytruda, Welireg, Reblozyl |
| Astellas Pharma US INC | $168.19 | 2023-2024 | Padcev, Xtandi, Xospata |
| Pharmaessentia USA Corporation | $167.85 | 2023-2024 | Besremi |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $146.46 | 2023-2025 | Fruzaqla, Alunbrig, Iclusig |
| Lilly USA, LLC | $144.97 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Sanofi-Aventis U.S. LLC | $141.98 | 2023-2024 | |
| Coherus Oncology, INC. | $140.07 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $139.67 | 2023-2024 | |
| Incyte Corporation | $115.29 | 2023-2025 | Jakafi, Monjuvi |
| Glaxosmithkline, LLC. | $105.19 | 2022-2025 | Zejula, Ojjaara |
| Servier Pharmaceuticals LLC | $105.16 | 2024-2025 | |
| Genentech USA, INC. | $95.50 | 2022-2025 | Tecentriq, Venclexta, Alecensa |
| Emd Serono, INC. | $95.44 | 2024-2025 | |
| Exelixis INC. | $89.13 | 2022-2025 | Cabometyx |
| Pharmacosmos Therapeutics INC. | $88.19 | 2024-2025 | Monoferric |
| Genmab U.S., INC. | $83.40 | 2023-2025 | Epkinly, Tivdak |
| Adaptive Biotechnologies Corporation | $77.88 | 2024-2025 | Clonoseq |
| Adc Therapeutics America, INC. | $62.56 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $62.37 | 2022-2025 | Libtayo |
| Amgen INC. | $58.23 | 2023 | Lumakras, Kyprolis |
| Rigel Pharmaceuticals, INC. | $54.49 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Geron Corporation | $52.11 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $49.08 | 2023 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $44.94 | 2023 | Onpattro |
| Taiho Oncology, INC. | $43.98 | 2023-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $41.34 | 2023 | Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $38.97 | 2024-2025 | |
| Pharming Healthcare, INC. | $37.64 | 2023-2024 | Ruconest |
| Mirati Therapeutics, INC. | $28.37 | 2024 | Krazati |
| Tersera Therapeutics LLC | $26.82 | 2024 | Xermelo |
| Ipsen Biopharmaceuticals, INC | $23.77 | 2024 | Onivyde, Somatuline Depot |
| Morphosys, US INC. | $23.75 | 2023 | Monjuvi |
| Agios Pharmaceuticals, INC. | $22.91 | 2025 | Pyrukynd |
| Iovance Biotherapeutics, INC. | $22.57 | 2025 | Amtagvi |
| Acrotech Biopharma INC. | $22.35 | 2023 | Beleodaq |
| Sobi, INC | $21.31 | 2023 | |
| Kyowa Kirin, INC. | $21.12 | 2025 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Cti Biopharma Corp. | $18.21 | 2023 | Vonjo |
| Tolmar Pharmaceuticals, INC. | $17.46 | 2022 | |
| Foundation Medicine, INC. | $17.41 | 2023 | Foundationone Liquid Cdx |
| Puma Biotechnology, INC. | $17.20 | 2025 | |
| Blueprint Medicines Corporation | $15.22 | 2024 | Ayvakit |
| Janssen Scientific Affairs, LLC | $11.21 | 2024 | Rybrevant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lani Stearns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.